Erascaincis A Clinical Stage Precision Oncology Company Based In San Diegocaliforniafounded In 2018The Company Is Dedicated Toerasing Cancerby Targeting The Ras Mapk Pathwaywhich Plays A Significant Role In Many Difficult To Treat Cancerserasca Focuses On Discoveringdevelopingand Commercializing Therapies For Patients With Ras Mapk Pathway Driven Cancersutilizing A Combination First Approach To Enhance Treatment Effectiveness Erasca S Pipeline Includes Several Clinical Stage Candidatessuch As Naporafenib For Nras Mutated Melanomaeras 801 For Egfr Altered Recurrent Glioblastomaand Eras 007 For Advanced Solid Tumorsthe Company Collaborates With Industry Leaders Like Novartis And Katmai Pharmaceuticals To Accelerate The Development Of Its Therapieswith Over $500 Million In Early Stage Funding And A Successful Ipo In 2021Erasca Is Well Positioned To Address Unmet Needs In Oncology And Improve Patient Outcomes
